Protocol Ledger

NCT06309485 · Phase II · RECRUITING

Phase 2 Study of WGI-0301 for Advanced HCC

Interventional Phase II clinical trial protocol NCT06309485 sponsored by Zhejiang Haichang Biotech Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-31 Enrollment: 60 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06309485
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06309485
Protocol FieldVerified Registry Value
NCT IdentifierNCT06309485
Consolidated Lead SponsorZhejiang Haichang Biotech Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment60 participants (ESTIMATED)
Registered Start Date2024-07-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI